Full Generic Medicine Info
Dosage/Direction for Use

Adult: Initially, 50 mg bid or tid, may be increased up to 100 mg bid or tid by the end of 1st wk, based on response. For severely depressed patient in hospital: Up to 600 mg daily.
Elderly: Initially, 25 mg bid or tid, may be increased up to 50 mg bid or tid by the end of 1st wk based on response. Max: 300 mg daily.
May be taken with or without food.
Acute recovery phase following MI. Concomitant or w/in 14 days of MAOI use.
Special Precautions
Patient w/ history of urinary retention, angle-closure glaucoma (w/o iridectomy), increased intraocular pressure; history of convulsive disorder, overt/latent seizure disorder; CV (e.g. MI, stroke, tachycardia, conduction abnormalities) and cerebrovascular diseases, hypovolaemia, decreased GI motility, paralytic ileus, BPH, xerostomia, visual problem, DM. Elderly. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor closely for clinical worsening, suicidality or unusual behavioural changes. Monitor heart rate, BP, and ECG esp in older adults and patient w/ pre-existing cardiac disease. Measure wt, BMI, and blood glucose.
Adverse Reactions
Drowsiness, dry mouth, constipation, blurred vision; anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alteration in EEG pattern, paraesthesia, tinnitus, disorientation, seizure, hypomania, numbness, incoordination, disturbed concentration, hyperthermia; oedema, skin rash, drug fever, urticaria, photosensitisation, pruritus, vasculitis, hepatitis; prolactin level elevation; nausea, epigastric distress, vomiting, flatulence, abdominal pain, peculiar taste, diarrhoea; dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration; disturbance of accommodation, mydriasis, delayed micturition, urinary retention, nasal stuffiness; hypotension, HTN, syncope, tachycardia; leucopenia, agranulocytosis; increased/decreased libido, impotence, menstrual irregularity, breast enlargement, galactorrhoea (in females), syndrome of inappropriate antidiuretic hormone secretion; lacrimation, wt gain/loss, altered liver function, painful ejaculation. Rarely, tardive dyskinesia.
Potentially Fatal: Rarely, neuroleptic malignant syndrome (NMS).
Symptoms: Grand mal convulsion, status epilepticus, coma, acidosis, acute tubular necrosis, rhabdomyolysis, myoglobinuria. Management: Symptomatic and supportive treatment w/ special attention to control of seizures. Induce emesis, then employ gastric lavage and activated charcoal. IV diazepam and/or phenytoin may be given to treat seizures.
Drug Interactions
May enhance the effects of barbiturates and other CNS depressants.
Potentially Fatal: May cause hypertensive crisis and severe convulsion w/ MAOIs.
Food Interaction
May enhance response to alcohol.
Amoxapine, a dibenzoxazepine TCA, is the N-desmethyl derivative of loxapine w/ actions similar to amitriptyline. It reduces the reuptake of norepinephrine and serotonin, and significantly blocks dopamine receptor activity.
Onset: 1-2 wk; may require 4-6 wk.
Absorption: Rapidly and well absorbed from the GI tract. Time to peak plasma concentration: W/in 1-2 hr.
Distribution: Widely distributed throughout body tissues. Enters breast milk. Volume of distribution: 0.9-1.2 L/kg. Plasma protein binding: Approx 90%.
Metabolism: Extensively metabolised in the liver via hydroxylation, principally to 8-hydroxyamoxapine (8-OH-amoxapine), and to a lesser extent, to 7-hydroxyamoxapine (7-OH-amoxapine). Metabolites undergo conjugation to form glucuronides.
Excretion: Via urine (mainly as glucuronides, <5% as unchanged drug). Elimination half-life: 8 hr; 30 hr (as 8-OH-amoxapine).
Oral: Store between 20-25°C.
CIMS Class
ATC Classification
N06AA17 - amoxapine ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.
Disclaimer: This information is independently developed by CIMS based on amoxapine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in